Eli Lilly and Dicerna Pharmaceuticalshave entered a global licensing and research collaboration focused on the discovery, development, and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners…
Lilly To Acquire AurKa Pharma
Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma is studying in Phase 1 clinical trials in…
Lilly To Acquire ARMO BioSciences
Eli Lilly and ARMO BioSciences, Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors. The…
FDA Advisory Committee Recommends Approval of Baricitinib 2mg, But Not 4mg
Eli Lilly and Company and Incyte Corporation announced early this week that the FDA Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously…
Lilly’s Taltz Psoriatic Arthritis Treatment Authorized For EU Marketing
Lilly receives EU marketing authorization for Taltz (ixekizumab) for the treatment of active psoriatic arthritis. Eli Lilly and Company announced that the European Commission has granted marketing authorization (MA) for Taltz (ixekizumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are…
